What is the treatment for infectious mononucleosis (mono)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Infectious Mononucleosis

Treatment is entirely supportive, as aciclovir does not ameliorate the course of infectious mononucleosis in otherwise healthy individuals. 1

Supportive Care Measures

The mainstay of management consists of:

  • Adequate hydration, analgesics, antipyretics, and rest guided by the patient's energy level 2. Enforced bed rest is not recommended; patients should adjust activity based on their own fatigue levels 2.

  • Reduction of activity as tolerated 3. Fatigue may be profound but typically resolves within three months, though myalgias and need for sleep may persist for several months after acute infection 2.

Medications NOT Routinely Recommended

  • Acyclovir has no role in routine treatment 1, 2. It does not improve clinical outcomes in immunocompetent patients 1.

  • Antihistamines are not recommended for routine treatment 2.

  • Corticosteroids should be reserved exclusively for airway obstruction or severe pharyngeal edema causing respiratory compromise 1, 2. They are not indicated for routine symptom management 2.

Activity Restrictions

  • Patients must be withdrawn from contact or collision sports for at least 4 weeks after symptom onset 2. More recent evidence suggests avoiding contact sports or strenuous exercise for 8 weeks or while splenomegaly persists 3.

  • Current guidelines recommend no athletic activity for 3 weeks from symptom onset, with shared decision-making to determine timing of return to activity 4. The conservative approach of 8 weeks is safer given that spontaneous splenic rupture occurs in 0.1-0.5% of patients and is potentially life-threatening 3.

Special Populations

Immunocompromised Patients

  • In immunocompromised patients with suspected primary EBV infection, immunomodulator therapy should be reduced or discontinued if possible 1.

  • These patients require specialist consultation due to increased risk of EBV-associated lymphoproliferative disease 1.

  • Obtain complete blood count, blood film, and liver function tests in patients on immunosuppressive therapy 1.

Children Under 10 Years

  • Primary EBV infection in children up to 10 years is usually asymptomatic or shows nonspecific courses 5. The heterophile antibody test can have false-negative results in children younger than 5 years 4.

Prevention Measures

  • Avoid sharing personal items contaminated with saliva and practice hand hygiene during outbreaks in close community settings 1. EBV is transmitted primarily through saliva 3, 5.

Common Pitfalls to Avoid

  • Do not prescribe antibiotics routinely, as infectious mononucleosis is viral 2, 3. If ampicillin or amoxicillin is given (often mistakenly for pharyngitis), a rash develops in 10-45% of cases 3.

  • Do not allow premature return to contact sports, as splenic rupture, though rare, can be fatal if not diagnosed early 3, 6.

  • Do not rely solely on heterophile antibody testing in the first week of illness or in young children, as false-negatives are common 2, 4.

References

Guideline

Diagnosis and Treatment of Infectious Mononucleosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Epstein-Barr virus infectious mononucleosis.

American family physician, 2004

Research

Infectious Mononucleosis: An Updated Review.

Current pediatric reviews, 2024

Research

Infectious Mononucleosis: Rapid Evidence Review.

American family physician, 2023

Research

[Infectious mononucleosis--a "childhood disease" of great medical concern].

Medizinische Monatsschrift fur Pharmazeuten, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.